For the quarter, the Voya MidCap Opportunities Fund underperformed the Index on a NAV basis due largely to selection effects.

The de-escalation of therapy helps avoid unnecessary toxicity from treatment in patients with brain cancer, explained Drs.

In conversation with Fierce Biotech’s Chris Hayden, Austin Read, head of PPD™ CorEvitas™ Precision Medicine, Thermo Fisher ...

China’s AI upstart DeepSeek shook the tech industry and stock markets earlier this year by proving to be amazingly capable despite accessing relatively limited resources, such as chips. It has gone on ...